16 U.S. States Reach $86M Settlement with Drug Manufacturer
-
By
July 26, 2024
-
2 min
-
1
Indivior reaches an $86 million settlement with 16 U.S. states over its alleged role in the opioid addiction crisis.
-
2
The settlement concerns buprenorphine-based products like Sublocade and Suboxone.
-
3
Indivior accused of improperly targeting sales to doctors running pill mills.
-
4
$86 million will be used over five years for opioid addiction treatment, recovery, and prevention.
-
5
Indivior remains a defendant in over 400 civil lawsuits related to opioid prescribing and usage.
-
Indivior, a drug manufacturer based in North Chesterfield, Virginia, has reached an $86 million settlement with 16 U.S. states over its alleged role in the opioid addiction crisis. The settlement concerns Indivior's manufacture of buprenorphine-based products, such as Sublocade and Suboxone, meant to treat opioid abuse but implicated in fueling addiction if misused. The company was accused of improperly targeting sales to doctors running pill mills and failing to monitor suspicious orders, leading to inappropriate prescriptions. The settlement funds will be used over five years for opioid addiction treatment, recovery, and prevention. Indivior remains a defendant in over 400 civil lawsuits related to opioid prescribing and usage.
-
1
Indivior reaches an $86 million settlement with 16 U.S. states over its alleged role in the opioid addiction crisis.
-
2
The settlement concerns buprenorphine-based products like Sublocade and Suboxone.
-
3
Indivior accused of improperly targeting sales to doctors running pill mills.
-
4
$86 million will be used over five years for opioid addiction treatment, recovery, and prevention.
-
5
Indivior remains a defendant in over 400 civil lawsuits related to opioid prescribing and usage.
Listen Tab content
